E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 3.1 SEK 6.16% Market Closed
Market Cap: 752.5m SEK

Wall Street
Price Targets

ENZY Price Targets Summary
Enzymatica AB (publ)

Wall Street analysts forecast ENZY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ENZY is 3.96 SEK with a low forecast of 2.71 SEK and a high forecast of 5.34 SEK.

Lowest
Price Target
2.71 SEK
13% Downside
Average
Price Target
3.96 SEK
28% Upside
Highest
Price Target
5.34 SEK
72% Upside
Enzymatica AB (publ) Competitors:
Price Targets
SAN
Sanofi SA
23% Upside
SHILPAMED
Shilpa Medicare Ltd
93% Upside
AJANTPHARM
Ajanta Pharma Ltd
15% Upside
326030
SK Biopharmaceuticals Co Ltd
33% Upside
6996
Antengene Corporation Ltd
47% Upside
LAURUSLABS
Laurus Labs Ltd
11% Downside
SUPN
Supernus Pharmaceuticals Inc
21% Upside
570
China Traditional Chinese Medicine Holdings Co Ltd
14% Downside

Revenue
Forecast

Revenue Estimate
Enzymatica AB (publ)

For the last 8 years the compound annual growth rate for Enzymatica AB (publ)'s revenue is 3%. The projected CAGR for the next 2 years is 56%.

3%
Past Growth
56%
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Enzymatica AB (publ)

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat

Net Income
Forecast

Net Income Estimate
Enzymatica AB (publ)

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ENZY's stock price target?
Price Target
3.96 SEK

According to Wall Street analysts, the average 1-year price target for ENZY is 3.96 SEK with a low forecast of 2.71 SEK and a high forecast of 5.34 SEK.

What is Enzymatica AB (publ)'s Revenue forecast?
Projected CAGR
56%

For the last 8 years the compound annual growth rate for Enzymatica AB (publ)'s revenue is 3%. The projected CAGR for the next 2 years is 56%.

Back to Top